PFE Earnings

PFE reported its earnings on 2026-02-03, showcasing a revenue of 17.56B against an estimate of 16.84B, resulting in a 4.26% surprise. The EPS was 0.66, surpassing the expected 0.56 by 17.86%. The stock experienced a -3.34% price change on the earnings day and a 2.1% change over the next five days, reflecting market reactions to the results.

Following PFE's earnings announcement on 2026-02-03, the stock price moved by -3.34% on the day of the release. Over the subsequent five days, it saw a 2.1% change. Historically, PFE's stock price tends to shift by an average of 0.17% in the 10 days leading up to earnings and -0.5% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate PFE's annual revenue to reach 13.98B, while the EPS is projected at 0.75. These estimates reflect recent revisions, with revenue estimates revised downward by -0.87% and EPS estimates revised downward by -2.65% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PFE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.87%, while EPS estimates moved revised downward by -2.65%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PFE's stock price typically moves by 0.17% in the 10 days before its earnings and -0.5% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.75 and revenue of 13.98B.

The earnings call summary indicates strong financial metrics with raised EPS guidance, significant cost savings initiatives, and ongoing product development in high-potential areas like lung cancer. Despite lower COVID-19 product performance, non-COVID products are doing well. The Q&A session revealed optimism about product pipelines and strategic AI investments. While some details were deferred, the overall sentiment is positive due to promising R&D advancements and strategic initiatives. The lack of specific market cap data limits precise impact prediction, but the positive aspects outweigh negatives, suggesting a positive stock reaction.